AlphaRx Completes Development of Vansolin(tm), a Vancomycin
Incorporating the Company's Proprietary Nanoparticle Delivery Platform, Indicated
in the Treatment of Life Threatening Infectious Diseases
Markham, ON September 30, 2005 -- AlphaRx Inc. (OTC BB:ALRX.OB - News)
today announced that it has completed the development of a novel
antibiotic formulation using its patent pending solid lipid nanoparticle
delivery platform. The new product is announced under the trade name
Vansolin™. The active ingredient is Vancomycin, a very powerful antibiotic
used mainly in hospitals to treat life threatening infectious disease
such as hospital acquired pneumonia, ventilator associated pneumonia and
severe sepsis. Vansolin™ is the Company’s fourth product employing
proprietary nanotechnology, a line of products which are intended to
increase the efficacy of the existing base drug compounds while reducing their
side effects.
Vancomycin was initially introduced over forty years ago to treat
evolving Penicillin-resistant strains of Staphylococci. Vancomycin is now
often employed as the drug of last-resort, the final treatment option
that a physician has to eliminate a bacterial infection resistant to other
antibiotic drugs.
The Company believes that encapsulating Vancomycin into a nanoparticle
formulation may increase its efficacy. According to published research
papers, in vitro uptake of Vancomycin nanoparticles by white blood
cells is 20 times greater than free drug. The Company anticipates that in
vivo, after IV infusion, white blood cells will readily absorb Vansolin™
nanoparticles and transport them to the site of inflammation and
infection, thereby increasing the local concentration of Vancomycin and
ultimately increasing its bactericidal effect.
The Company has previously announced and outlined the clinical
development strategy of Zysolin™, a novel antibiotic nanoparticle formulation
indicated for the treatment of hospital acquired pneumonia. Vansolin™
will be developed using the same clinical development strategy. The
Company expects to advance Vansolin™ into the clinical phase during the
fourth quarter of 2006.
About AlphaRx Inc. (www.AlphaRx.com)
AlphaRx is an emerging biopharmaceutical company utilizing proprietary
drug delivery technology to develop novel formulations of drugs that
are insoluble or poorly soluble in water or have yet to be administrable
to the human body with an acceptable delivery method. The Company’s
product candidates address various pharmaceutical markets, including
arthritis, tuberculosis, ocular infection, ocular inflammation and hospital
acquired pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and
pursuant to the Safe Harbor provisions of the Securities Litigation
Reform Act of 1995 and involve risks and uncertainties that may
individually or mutually impact the matters herein described, including but not
limited to product development and acceptance, manufacturing,
competition, regulatory and/or other factors, which are outside the control of
the Company.
AI
